Brain uptake of iodine-131 metaiodobenzylguanidine following therapy of malignant pheochromocytoma

Simple item page
dc.contributor.authorDwamena B.A.
dc.contributor.authorZempel S.
dc.contributor.authorKlopper J.F.
dc.contributor.authorVan Heerden B.
dc.contributor.authorWieland D.
dc.contributor.authorShapiro B.
dc.contributor.authorDwamena B.A.
dc.contributor.authorZempel S.
dc.contributor.authorKlopper J.F.
dc.contributor.authorVan Heerden B.
dc.contributor.authorWieland D.
dc.contributor.authorShapiro B.
dc.date.accessioned2011-05-15T16:16:07Z
dc.date.accessioned2011-05-15T16:16:07Z
dc.date.available2011-05-15T16:16:07Z
dc.date.available2011-05-15T16:16:07Z
dc.date.issued1998
dc.date.issued1998
dc.description.abstractIntracranial metaiodobenzylguanidine (MIBG) uptake is occasionally and only faintly visualized on diagnostic studies. Recently, intense normal cerebellar uptake was described on posttherapy MIBG images. Experience at the University of Michigan with posttherapy MIBG scintigraphy of pheochromocytoma was reviewed. The patterns and correlates of intracranial uptake after therapeutic I-131 MIBG in 25 patients (61 patient treatment encounters) were evaluated by review of records and blinded consensus interpretation of diagnostic and posttherapeutic MIBG scans. Thirty-nine (64%) patient treatment encounters demonstrated at least faint (grade 1) MIBG uptake in one or more brain sites; the most common site was the cerebellum. There was a statistically significant relation between intracranial uptake and 1) size of therapeutic dose and 2) patient age, but no relation between intracranial uptake and gender, body mass index, plasma epinephrine level, plasma norepinephrine level, urine metanophrine level, or the therapy-to-imaging interval. Although the influence of age on the pattern and intensity of intracranial uptake is unexplained, the relation to therapy dose may be explained by the possible generation of MIBG metabolites that can cross the blood-brain barrier (high activity administered and the delay until imaging). Further studies are needed to define mechanisms of intracranial uptake and relation to responses and toxicity after MIBG therapy of neuroendocrine tumors.
dc.description.abstractIntracranial metaiodobenzylguanidine (MIBG) uptake is occasionally and only faintly visualized on diagnostic studies. Recently, intense normal cerebellar uptake was described on posttherapy MIBG images. Experience at the University of Michigan with posttherapy MIBG scintigraphy of pheochromocytoma was reviewed. The patterns and correlates of intracranial uptake after therapeutic I-131 MIBG in 25 patients (61 patient treatment encounters) were evaluated by review of records and blinded consensus interpretation of diagnostic and posttherapeutic MIBG scans. Thirty-nine (64%) patient treatment encounters demonstrated at least faint (grade 1) MIBG uptake in one or more brain sites; the most common site was the cerebellum. There was a statistically significant relation between intracranial uptake and 1) size of therapeutic dose and 2) patient age, but no relation between intracranial uptake and gender, body mass index, plasma epinephrine level, plasma norepinephrine level, urine metanophrine level, or the therapy-to-imaging interval. Although the influence of age on the pattern and intensity of intracranial uptake is unexplained, the relation to therapy dose may be explained by the possible generation of MIBG metabolites that can cross the blood-brain barrier (high activity administered and the delay until imaging). Further studies are needed to define mechanisms of intracranial uptake and relation to responses and toxicity after MIBG therapy of neuroendocrine tumors.
dc.description.versionArticle
dc.description.versionArticle
dc.identifier.citationClinical Nuclear Medicine
dc.identifier.citation23
dc.identifier.citation7
dc.identifier.citationClinical Nuclear Medicine
dc.identifier.citation23
dc.identifier.citation7
dc.identifier.issn03639762
dc.identifier.issn03639762
dc.identifier.other10.1097/00003072-199807000-00009
dc.identifier.other10.1097/00003072-199807000-00009
dc.identifier.urihttp://hdl.handle.net/10019.1/13637
dc.identifier.urihttp://hdl.handle.net/10019.1/13637
dc.subjectadrenalin; metadrenalin; noradrenalin; adolescent; adrenalin blood level; adult; aged; article; blood brain barrier; brain scintiscanning; catecholamine urine level; cerebellum; clinical protocol; controlled study; female; human; intravenous drug administration; isotope labeling; major clinical study; male; medical record; noradrenalin blood level; pheochromocytoma; 3-Iodobenzylguanidine; Adolescent; Adrenal Gland Neoplasms; Adrenergic Agonists; Adrenergic alpha-Agonists; Adult; Age Factors; Aged; Blood-Brain Barrier; Body Mass Index; Brain; Cerebellum; Epinephrine; Evaluation Studies; Female; Humans; Male; Metanephrine; Middle Aged; Neuroendocrine Tumors; Norepinephrine; Pheochromocytoma; Radiopharmaceuticals; Radiotherapy Dosage; Retrospective Studies; Sex Factors; Single-Blind Method
dc.subjectadrenalin
dc.subjectmetadrenalin
dc.subjectnoradrenalin
dc.subjectadolescent
dc.subjectadrenalin blood level
dc.subjectadult
dc.subjectaged
dc.subjectarticle
dc.subjectblood brain barrier
dc.subjectbrain scintiscanning
dc.subjectcatecholamine urine level
dc.subjectcerebellum
dc.subjectclinical protocol
dc.subjectcontrolled study
dc.subjectfemale
dc.subjecthuman
dc.subjectintravenous drug administration
dc.subjectisotope labeling
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectmedical record
dc.subjectnoradrenalin blood level
dc.subjectpheochromocytoma
dc.subject3-Iodobenzylguanidine
dc.subjectAdolescent
dc.subjectAdrenal Gland Neoplasms
dc.subjectAdrenergic Agonists
dc.subjectAdrenergic alpha-Agonists
dc.subjectAdult
dc.subjectAge Factors
dc.subjectAged
dc.subjectBlood-Brain Barrier
dc.subjectBody Mass Index
dc.subjectBrain
dc.subjectCerebellum
dc.subjectEpinephrine
dc.subjectEvaluation Studies
dc.subjectFemale
dc.subjectHumans
dc.subjectMale
dc.subjectMetanephrine
dc.subjectMiddle Aged
dc.subjectNeuroendocrine Tumors
dc.subjectNorepinephrine
dc.subjectPheochromocytoma
dc.subjectRadiopharmaceuticals
dc.subjectRadiotherapy Dosage
dc.subjectRetrospective Studies
dc.subjectSex Factors
dc.subjectSingle-Blind Method
dc.titleBrain uptake of iodine-131 metaiodobenzylguanidine following therapy of malignant pheochromocytoma
dc.titleBrain uptake of iodine-131 metaiodobenzylguanidine following therapy of malignant pheochromocytoma
dc.typeArticle
dc.typeArticle
Files
Collections
Stellenbosch University - Scopus Tygerberg Hospital Publications